secwatch.observer — SEC 8-K summary
======================================

Issuer:     Xeris Biopharma Holdings, Inc. (XERS)
CIK:        0001867096
Form:       8-K
Filed at:   2023-01-05T23:59:59+00:00
Accession:  0001867096-23-000003
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Xeris expects 2022 net product revenue at top of $105M-$110M guidance, cash >$120M
--------------------------------------------------------------------------------

- Expects 2022 net product revenue at top of guidance range of $105M-$110M.
- Year-end cash, cash equivalents, and short-term investments >$120M, above previous $110M-$120M range.
- FDA approved a generic version of Keveyis (dichlorphenamide); company believes it can defend the franchise.
- Does not anticipate need to raise equity to fund operations, citing commercial momentum and cash position.
- Q4 and FY22 financial results to be reported on or about March 8, 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1867096/000186709623000003/0001867096-23-000003-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1867096/000186709623000003/xers-20230105.htm
  HTML page:      https://secwatch.observer/filing/0001867096-23-000003

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer